TSH BIOPHARM CORPORATION LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.3 TWD | +2.20% |
|
+10.24% | +19.88% |
| Mar. 11 | TSH Biopharm Corporation Limited Announces Directorate Changes on April 1, 2024 | CI |
| Mar. 11 | TSH Biopharm Corporation Limited Appoints Jung-Liang Kao as CFO on April 1, 2024 | CI |
| Sales 2022 | 464M 14.25M | Sales 2023 | 811M 24.89M | Capitalization | 1.93B 59.29M |
|---|---|---|---|---|---|
| Net income 2022 | 61M 1.87M | Net income 2023 | 62M 1.9M | EV / Sales 2022 | 2.38 x |
| Net cash position 2022 | 722M 22.17M | Net cash position 2023 | 765M 23.47M | EV / Sales 2023 | 1.44 x |
| P/E ratio 2022 |
29.5
x | P/E ratio 2023 |
31.2
x | Employees | 76 |
| Yield 2022 |
3.36% | Yield 2023 |
2.54% | Free-Float | 35.47% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +2.20% | ||
| 1 week | +10.24% | ||
| Current month | +5.42% | ||
| 1 month | +6.91% | ||
| 3 months | +20.60% | ||
| 6 months | +32.53% | ||
| Current year | +19.88% |
1 week
56.50
62.00
1 month
54.4062.40
Current year
49.1066.70
1 year
44.3066.70
3 years
38.8066.70
5 years
38.8082.50
10 years
34.95114.50
| Managers | Title | Age | Since |
|---|---|---|---|
Ssu Yuan Yang
CEO | Chief Executive Officer | - | - |
Chen Ju Kan
DFI | Director of Finance/CFO | - | 10-08-31 |
Shu Ping Huang
ADM | Chief Administrative Officer | - | 10-08-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kang Chi Chou
BRD | Director/Board Member | - | - |
Chuan Lin
CHM | Chairman | 72 | - |
Hsin Yang Liu
PRN | Corporate Officer/Principal | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 60.3 | +2.20% | 279,007 |
| 24-04-25 | 59 | -0.84% | 175,652 |
| 24-04-24 | 59.5 | -1.98% | 228,936 |
| 24-04-23 | 60.7 | +7.05% | 513,919 |
| 24-04-22 | 56.7 | +3.66% | 226,509 |
End-of-day quote Taipei Exchange, April 25, 2024
More quotes
Tsh biopham corporation ltd. is a Taiwan-based company principally engaged in the manufacturing and distribution of medical preparations. The Company primarily provides medicines for cardiovascular, including Amtrel, Rytmonorm, Licodin, Isormol and ISOPTIN SR; medicines for intestines and stomach, including MOPRIDE, Catilon, Gastro-Timelet and Ribarin, and medicines for central nervous, including Aleviatin, Lonine and Lacoxa SR. The Company distributes its products mainly in domestic markets.
Sector
Pharmaceuticals
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +19.88% | 70.98M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 8432 Stock
